source
- Novo and Novartis see heart drug setbacks as trials show minimal efficacyNovo's cardiovascular candidate failed to demonstrate meaningful benefit in its pivotal study, causing the company's shares to fall about 9% in July. The trial data showed the drug had little effe…
- Democrats Take House, Raising Questions for Biopharma PolicyDemocrats secured control of Congress in a wave election held on Tuesday, shifting the political balance in Washington. The change is expected to influence the regulatory landscape for the biophar…